Earnings Call Summary | EHealth(EHTH.US) Q2 2024 Earnings Conference
Earnings Call Summary | EHealth(EHTH.US) Q2 2024 Earnings Conference
Adjusted The following is a summary of the EHealth, Inc. (EHTH) Q2 2024 Earnings Call Transcript:
以下是易康公司（EHTH）2024年第二季度业绩会的摘要:
Financial Performance:
金融业绩：
eHealth reported a Q2 total revenue of $65.9 million, a slight decline of 1% year-over-year.
Excluding tail revenue, total revenue for the quarter increased 13% year-over-year.
Adjusted EBITDA improved by $6.5 million year-over-year, excluding impact of restructuring and impairment charges and tail revenue.
GAAP net loss was $28 million, compared to a loss of $23.5 million the previous year.
易康报告Q2总营业收入为6590万美元，同比略微下降1%。
除去尾部收入，本季度总营业收入同比增长13%。
除去重组和减值费用和尾部收入的影响，调整后的EBITDA同比增加了650万美元。
GAAP净亏损为2800万美元，相比上一年的2350万美元亏损有所增加。
Business Progress:
业务进展：
eHealth experienced a 16% increase in Medicare submissions year-over-year.
The company launched several new customer retention strategies and saw improvements in Medicare segment profit by $6.1 million year-over-year, excluding tail revenue.
eHealth's carrier-dedicated platform, Amplify, saw strong enrollment volumes and conversion rates, and onboarded a new customer during Q2.
易康的医保提交数量同比增加了16%。
公司推出了多种新的客户保留策略，并且除去尾部收入，医保部门利润同比增加了610万美元。
易康的专用载体平台Amplify在第二季度表现强劲，注册数量和转化率高，并成功在Q2引进了一位新客户。
Opportunities:
机会：
The anticipated Medicare plan changes provide an opportunity for eHealth to drive strong consumer demand to its platform during the enrollment season.
预期的医保计划变更为易康在报名季节期间推动强劲的消费者需求提供了机会。
Risks:
风险：
The upcoming CFO transition and CEO's planned retirement might impact the company's operational continuity and leadership stability.
即将进行的CFO转型和CEO计划退休可能会对公司的运营连续性和领导稳定性产生影响。
More details: eHealth IR
更多详情请参考易康IR。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章内容的准确性无法完全保证。有关更全面的详细信息，请参阅IR网站。本文只是为投资者提供参考，没有任何指导或推荐建议。